87704916LUC1001
Lung cancer
INTRATUMORAL STUDY.
A Phase 1 study of intratumoral administration of JNJ-87704916 (oncolytic virus) as monotherapy and in combination for advanced solid tumors/mNSCLC
Phase
Compound
JNJ-87704916 (oncolytic virus) ± cetrelimab (anti–PD-1 mAb)
NCT identifier
NCT06311578
Enrollment
N=~96
For more information, including
contact details, please visit
the J&J Clinical Trial Finder
contact details, please visit
the J&J Clinical Trial Finder
Study overview & design
Key eligibility criteria*:
- Part 1: advanced solid tumors that have progressed on standard therapies
- Parts 1 and 2: ≥1 injectable lesion
- Part 2: ≥1 evaluable uninjected lesion
- Part 2 Cohort A: mNSCLC without actionable mutations that have progressed on standard therapies
- Part 2 Cohort B: previously untreated mNSCLC with PD-L1 ≥50%
Study
design
Primary outcomes†:
- Selected dose
- Safety
Secondary outcome:
- Preliminary efficacy
*Not a complete list of inclusion and exclusion criteria. †Not a complete list of outcomes.
1L, first line; 2L+, second line plus; IT, intratumoral; mNSCLC, metastatic non–small cell lung cancer; PD-L1, programmed cell death ligand 1.